Decrease in Heart Rate Below Baseline Value Clinical Trial
Official title:
A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol
Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD
and hypertension. However, there is large interindividual variability in the response to
beta blockers.
The hypothesis underlying this study is that genetic differences between individuals will
determine the individual response to esmolol, a betablocker that is administered
intravenously. Esmolol will be administered intravenously to healthy volunteers, and the
effects on heart rate and blood pressure will be monitored. In addition, we will measure
plasma renin activity and plasma levels of norepinephrine.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science